3 Oil and Gas Exploration Company, Steel Tubes and Forgings Maker and Pharmaceutical Maker Stocks With a Strong Future Roadmap: Oil and Natural Gas Corporation, Goodluck India and Strides Pharma Science

Oil explorer, steel tube and generic drug stocks give investors a way to track businesses that sit close to everyday demand in India. Oil and Natural Gas Corporation, Goodluck India and Strides Pharma Science cover an oil and gas exploration company, a steel tubes and forgings maker and a pharmaceutical maker.

This list covers three oil explorer, steel tube and generic drug stocks with complete current figures: Oil and Natural Gas Corporation, Goodluck India and Strides Pharma Science. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Oil Explorer, Steel Tube and Generic Drug Stocks?

Oil explorer, steel tube and generic drug stocks are listed companies that explore for and produce crude oil and natural gas, make welded steel tubes, pipes and forged products for industry and infrastructure, and make branded and generic medicines for regulated markets. Their earnings depend on oil and gas output, infrastructure spending and pharma sales.

Oil Explorer, Steel Tube and Generic Drug Stocks at a Glance

On valuation, Oil and Natural Gas Corporation and Strides Pharma Science trade at a P/E below the industry P/E, while Goodluck India trades above it, which reflects the growth the market already expects. Readers comparing oil explorer, steel tube and generic drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in oil explorer, steel tube and generic drug stocks can use the coming numbers to test whether growth is holding.

Why Do Oil Explorer, Steel Tube and Generic Drug Stocks Have a Strong Roadmap in India?

Oil explorer, steel tube and generic drug stocks have a strong roadmap in India because steady energy demand, heavy spending on pipelines and industry and growing global demand for generic medicines keep widening the market for these companies.

• Oil and gas. The economy needs steady fuel supply.
• Steel tubes. Pipelines and plants need strong tubes.
• Pharma. Generic medicines reach more markets.

Why Oil and Natural Gas Corporation Features Among These Oil Explorer, Steel Tube and Generic Drug Stocks

Among the oil explorer, steel tube and generic drug stocks on this list, Oil and Natural Gas Corporation is India's largest producer of crude oil and natural gas, with operations in domestic basins and overseas assets. It also has interests in refining, petrochemicals and gas through group companies.

The company has a return on equity of 11.1%, a debt to equity ratio of 0.47 and a market capitalisation of Rs 282,679 crore. The stock trades at a P/E of 6.3, below the industry P/E of 7.2.

Revenue rose from Rs 498,738 crore in FY22 to Rs 621,019 crore in FY26, a compound annual growth rate of 5.6%. Net profit grew from Rs 32,778 crore in FY23 to Rs 49,793 crore in FY26, which works out to a compound annual growth rate of 15.0%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 207,776 crore.

Roadmap: The company is investing in new wells, deepwater projects and field redevelopment to raise output, and it is entering new energy areas such as gas and renewables. Its large reserve base supports long-term production.

What to watch: Follow production volumes, new field start-ups and realisations.

Why Goodluck India Features Among These Oil Explorer, Steel Tube and Generic Drug Stocks

Among the crude producer, pipe maker and medicine shares on this list, Goodluck India makes steel tubes and pipes, forgings and tower structures for engineering, power, infrastructure and construction customers.

Revenue rose from Rs 2,617 crore in FY22 to Rs 4,121 crore in FY26, a compound annual growth rate of 12.0%. Net profit grew from Rs 75.0 crore in FY22 to Rs 183 crore in FY26, which works out to a compound annual growth rate of 24.9%.

In the June 2026 quarter, revenue grew 30.9% year on year to Rs 1,292 crore, while net profit rose 67.4% to Rs 67.2 crore. The company has a return on equity of 12.1%, a debt to equity ratio of 0.75 and a market capitalisation of Rs 5,520 crore. The stock trades at a P/E of 26.3, above the industry P/E of 20.4.

Roadmap: The company is expanding its tubes and forgings capacity and growing its supply of tower structures for power transmission. Infrastructure spending supports demand for its steel products.

What to watch: Monitor order inflows, steel prices and demand from infrastructure projects.

Why Strides Pharma Science Features Among These Oil Explorer, Steel Tube and Generic Drug Stocks

Among the three companies on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.

In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%.

Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.

Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What to watch: Track new US launches and the pace of price erosion in generic categories.

Oil and Natural Gas Corporation vs Goodluck India vs Strides Pharma Science on Key Financials

The table below sets the three oil explorer, steel tube and generic drug stocks side by side on revenue, profit and margin, using reported figures.

Strides Pharma Science posts the highest return on equity in this group at 17.9%. Oil and Natural Gas Corporation has the largest FY26 revenue at Rs 621,019 crore, and Goodluck India shows the fastest revenue growth with a 12.0% compound annual rate. A useful habit with oil explorer, steel tube and generic drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several upstream oil and gas, forged tube and pharma stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Oil Explorer, Steel Tube and Generic Drug Stocks

Every theme carries risks that deserve a check before any decision. For these oil explorer, steel tube and generic drug stocks, the main points are: Long-term crude producer, pipe maker and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio. Tracking promoter holding and management commentary adds context when you study crude producer, pipe maker and medicine shares.

• Oil and gas prices. Earnings follow crude oil, gas and refining margins.
• Capex cycles. Customer spending on plants and projects can vary.
• Pricing pressure. Generic prices can change by market.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter oil explorer, steel tube and generic drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Oil Explorer, Steel Tube and Generic Drug Stocks

Oil explorer, steel tube and generic drug stocks work best when investors track growth, valuation and return on equity side by side. Oil and Natural Gas Corporation, Goodluck India and Strides Pharma Science each have a clear plan to grow. Based on the 11 November 2026 close, Oil and Natural Gas Corporation trades at Rs 226.8, Goodluck India at Rs 559.7 and Strides Pharma Science at Rs 999.4. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these oil explorer, steel tube and generic drug stocks to a watchlist. Peer comparison is the simplest way to judge oil explorer, steel tube and generic drug stocks, because sector averages show whether a company's margins and returns are ordinary or exceptional.

Download the Univest iOS App or Univest Android App to track oil explorer, steel tube and generic drug stocks, set price alerts and get research-backed stock ideas.

What are oil explorer, steel tube and generic drug stocks?

Ans. Oil explorer, steel tube and generic drug stocks are listed companies that explore for and produce crude oil and natural gas, make welded steel tubes, pipes and forged products for industry and infrastructure, and make branded and generic medicines for regulated markets. Their earnings depend on oil and gas output, infrastructure spending and pharma sales. This list looks at three of them, Oil and Natural Gas Corporation, Goodluck India and Strides Pharma Science, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which oil explorer, steel tube and generic drug stocks are covered in this list?

Ans. This list covers Oil and Natural Gas Corporation, Goodluck India and Strides Pharma Science. Based on the 11 November 2026 close, Oil and Natural Gas Corporation traded at Rs 226.8, Goodluck India at Rs 559.7 and Strides Pharma Science at Rs 999.4. Their return on equity ranges from 11.1% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.6% to 12.0%.

Why do oil explorer, steel tube and generic drug stocks have a strong future roadmap in India?

Ans. Oil explorer, steel tube and generic drug stocks have a strong roadmap in India because steady energy demand, heavy spending on pipelines and industry and growing global demand for generic medicines keep widening the market for these companies. The main drivers are as follows. Oil and gas. The economy needs steady fuel supply. Steel tubes. Pipelines and plants need strong tubes. Pharma. Generic medicines reach more markets. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Oil and Natural Gas Corporation performed financially?

Ans. Revenue rose from Rs 498,738 crore in FY22 to Rs 621,019 crore in FY26, a compound annual growth rate of 5.6%. Net profit grew from Rs 32,778 crore in FY23 to Rs 49,793 crore in FY26, which works out to a compound annual growth rate of 15.0%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 207,776 crore. The company has a return on equity of 11.1%, a debt to equity ratio of 0.47 and a market capitalisation of Rs 282,679 crore. The stock trades at a P/E of 6.3, below the industry P/E of 7.2. Looking ahead, the company is investing in new wells, deepwater projects and field redevelopment to raise output, and it is entering new energy areas such as gas and renewables. Its large reserve base supports long-term production.

How has Goodluck India performed financially?

Ans. Revenue rose from Rs 2,617 crore in FY22 to Rs 4,121 crore in FY26, a compound annual growth rate of 12.0%. Net profit grew from Rs 75.0 crore in FY22 to Rs 183 crore in FY26, which works out to a compound annual growth rate of 24.9%. In the June 2026 quarter, revenue grew 30.9% year on year to Rs 1,292 crore, while net profit rose 67.4% to Rs 67.2 crore. The company has a return on equity of 12.1%, a debt to equity ratio of 0.75 and a market capitalisation of Rs 5,520 crore. The stock trades at a P/E of 26.3, above the industry P/E of 20.4. Looking ahead, the company is expanding its tubes and forgings capacity and growing its supply of tower structures for power transmission. Infrastructure spending supports demand for its steel products.

How has Strides Pharma Science performed financially?

Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What risks should investors check before buying oil explorer, steel tube and generic drug stocks?

Ans. Investors should check a few risks before buying oil explorer, steel tube and generic drug stocks. Oil and gas prices. Earnings follow crude oil, gas and refining margins. Capex cycles. Customer spending on plants and projects can vary. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of oil explorer, steel tube and generic drug stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.